Canine cyclin T1 rescues equine infectious anemia virus tat trans- activation in human cells

Virology

Volumn 268, Issue 1, 2000, Pages 7-11

  Albrecht, Todd R ^a   Lund, Lars H ^a   Garcia Blanco, Mariano A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN T1; CYCLINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN; HUMAN CELL; LENTIVIRINAE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; RNA VIRUSES;

EID: 0034009884     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.0141     Document Type: Article

References (14)

1. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17:1998;7056-7065.
2. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol. Cell Biol. 19:1999;4592-4599.
3. Carroll R., Martarano L., Derse D. Identification of lentivirus Tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras. J. Virol. 65:1991;3460-3467.
4. Carroll R., Peterlin B. M., Derse D. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J. Virol. 66:1992;2000-2007.
5. Cullen B. R. HIV-1 auxiliary proteins: making connections in a dying cell. Cell. 93:1998;685-692.
6. Dorn P., DaSilva L., Martarano L., Derse D. Equine infectious anemia virus tat: Insights into the structure, function and evolution of lentivirus trans-activator proteins. J. Virol. 64:1990;1616-1624.
7. Jones K. A. Taking a new TAK on Tat transactivation. Genes Dev. 11:1997;2593-2599.
8. Garber M. E., Wei P., KewalRamani V. N., Mayall T. P., Herrmann C. H., Rice A. P., Littman D. R., Jones K. A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:1998;3512-3527.
9. Madore S. J., Cullen B. R. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. J. Virol. 67:1993;3703-3711.
10. Tanaka M., Winship H. Differential transcription activation by Oct-1 and Oct-2: Interdependent activation domains induce Oct-2 phosphorylation. Cell. 60:1990;375-386.
11. Sune C., Hayashi T., Liu Y., Lane W. S., Young R. A., Garcia-Blanco M. A. CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. Mol. Cell Biol. 17:1997;6029-6039.
12. Sune C., Garcia-Blanco M. A. Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. Mol. Cell Biol. 19:1999.
13. Peng J., Zhu Y., Milton J. T., Price D. H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:1998;755-762.
14. Wei P., Garber M. E., Fang S., Fischer W. H., Jones K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.